Choose   Change
BGI Advancing Genomics Together
BGI Advancing Research
BGI Advancing Drug Discovery
BGI Advancing Healthcare
News
/by

International Sc2.0 Project On Track to Build World’s First Synthetic Yeast Genome

March 9th, 2017 – Shenzhen. A team from the international Synthetic Yeast Genome Project (Sc2.0 project) have announced the completion of the de novo redesign and synthesis of five more chromosomes of Saccharomyces cerevisiae; chromosomes II, V, VI, X and XII. The researchers also performed an in-depth, multi-dimensional analysis on the yeast strain, and confirmed that the phenotype of the synthetic yeast strain is consistent to that of the wild-type.
Spotlight
/by

Gene Expression Sequencing at Array Prices!

The higher cost of NGS has prevented routine adoption of RNA sequencing, until now. BGI is proud to introduce Gene Expression Sequencing Services, with all the benefits from NGS data, but at a cost that is comparable to that of microarrays.

Discover BGI’s Exome Sequencing Service

– 100 bp and 150bp Paired End sequencing options available
– Guaranteed ≥ 80% of bases with quality score of ≥Q30
–  CAP compliant facility in Hong Kong
–  US FDA 21 CFR Part 11 compliant processes

RCOG conference BGI
Events
/by

BGI will be at RCOG 2017

BGI will be attending the Royal College of Obstetricians and Gynaecologists 2017 Annual Conference in Cape Town, South Africa, 20-22 March. We'll be at booth 52. Come and say hello and learn more about our wide range of genomics solutions across reproductive healthcare.

Don’t hesitate to contact us to request a quote or to talk more about your requirements and how we can support your needs.

About BGI

BGI was founded in 1999 as a nonprofit research organization. Over the years, BGI has grown into a multinational genomics company with significant global operations and a wide variety of next generation sequencing (NGS) services including whole genome sequencing, exome sequencing and RNA sequencing. With more than 5,000 employees across the globe and R&D, manufacturing, and commercial operations around the world, BGI is committed to providing genomics solutions to address the research, pharmaceutical, and clinical markets while utilizing the power of NGS technology in order to improve human health and empower large-scale human, plant, and animal genomics research.

________________________________________________________________________________________

9

Offices

On 5

Continents

With over 5000

Employees

Copyright © BGI 2016